{"id":"NCT02263079","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase","officialTitle":"A Phase IIIb, Randomized, Open-Label Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Patients in Children With HBeAg Positive Chronic Hepatitis B in the Immune-Tolerant Phase","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-06-16","primaryCompletion":"2020-01-29","completion":"2020-01-29","firstPosted":"2014-10-13","resultsPosted":"2020-08-24","lastUpdate":"2020-08-24"},"enrollment":62,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Pediatric Immuno-Tolerant Chronic Hepatitis B"],"interventions":[{"type":"DRUG","name":"Entecavir","otherNames":[]},{"type":"DRUG","name":"Lamivudine","otherNames":[]},{"type":"DRUG","name":"Pegylated Interferon Alfa-2A","otherNames":["Pegasys, Peg-IFN-Alfa-2A"]}],"arms":[{"label":"Peg-IFN-Alfa-2A + Lamivudine or Entecavir","type":"EXPERIMENTAL"},{"label":"Untreated Control Participants","type":"NO_INTERVENTION"},{"label":"Peg-INF-Alfa-2A Monotherapy","type":"EXPERIMENTAL"}],"summary":"This randomized, controlled, parallel group, open-label multicenter study will evaluate the efficacy and safety of a combination of pegylated interferon alfa-2A (Pegasys) plus lamivudine or entecavir compared with an untreated control group in participants with HBeAg positive CHB in the immune tolerant phase. NOTE: STUDY RECRUITMENT HAS BEEN TERMINATED","primaryOutcome":{"measure":"Percentage of Participants With Loss of Hepatitis B Surface Antigen (HBsAg) at 24 Weeks Post-End of Treatment/End of Untreated Observation","timeFrame":"24 weeks post-treatment/at the end of untreated observation (Week 80)","effectByArm":[{"arm":"Peg-IFN-Alfa-2A + Lamivudine or Entecavir","deltaMin":3.8,"sd":null},{"arm":"Untreated Control Participants","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"3 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":11},"locations":{"siteCount":25,"countries":["United States","Australia","Belgium","Germany","Italy","Malaysia","Romania","Russia","Taiwan","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":26},"commonTop":["HEADACHE","PYREXIA","ABDOMINAL PAIN UPPER","NAUSEA","FATIGUE"]}}